Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DSM Wins Paranta Bio-Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

DSM Wins Paranta Bio-Contract

Will provide process development, manufacture at Australian Facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM Pharmaceutical Products has signed a biologics contract with Paranta Biosciences under which DSM will provide the process development and cGMP manufacture of Follistatin, Paranta’s lead recombinant human protein, at its Brisbane facility. Financial terms were not disclosed.

Alexander Wessels, chief executive officer of DSM Pharmaceutical Products, said, “Working with Paranta is an important milestone for DSM to support the local client base directly from our facility in Australia, expanding our presence in global regions. Our collaboration with Biopharmaceuticals Australia (BPA), the Queensland Government and the Australian Commonwealth Government is already bringing benefits to Australia by providing biopharma firms local support and manufacturing expertise.”

Ross Barrow, chief executive officer of Paranta Biosciences, said, “Follistatin has been shown to have great potential in treating a wide range of inflammatory and fibrotic respiratory diseases, which affect over 300 million people worldwide. Our selection of DSM as Paranta’s biologics manufacturing partner is the culmination of an extensive global search process spanning more than nine months. We are looking forward to working with the Groningen and Brisbane groups of DSM Biologics as we continue the development and manufacturing scale-up of what we believe will be a truly exciting biotherapeutic.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics